Abstract
Concentration measurements of antipsychotic drugs may be useful in monitoring patient compliance and in evaluating adverse drug effects (Dahl 1986). Poor compliance seems to be underestimated as a source of drug failure (Hulka et al. 1976). The problem is of daily concern in psychiatric hospitals as well as at outpatient centres and in private practice. As a consequence, many physicians and psychiatrists are misled in their efforts to establish the right dose. Variable compliance, resulting in wide daily fluctuations of drug concentrations, may increase the risk of developing toxic symptoms and tardive dyskinesia (Kane et al. 1985), a hazard which seems to increase with dose and the length of treatment (Casey 1985). Poor compliance may also lead to abandoning a potentially good medicine on false premises.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Baldessarini RJ, Cohen BM, Teicher MH (1988) Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 45: 79–91
Bolvig Hansen L, Larsen NE (1985) Therapeutic advantages of monitoring plasma concentrations of perphenazine in clinical practice. Psychopharmacology (Berlin) 87: 16–19
Bolvig Hansen L, Larsen NE, Gulmann N (1982) Dose-response relationships of perphenazine in the treatment of acute psychoses. Psychopharmacology (Berlin) 78: 112–115
Brösen K, Gram LF (1988) First-pass metabolism of imipramine and desipramine: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 40: 543–549
Casey DE (1985) Tardine dyskinesia: reversible and irreversible. In: Casey DE, Chase TN, Christensen AV, Gerlach J (eds) Dyskinesia research and treatment. Springer, Berlin Heidelberg New York, pp 88–97
Dahl SG (1982) Active metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effect. Ther Drug Monit 4: 33–40
Dahl SG (1986) Plasma level monitoring of antipsychotic drugs. Clinical utility. Clin Pharmacokinet 11: 36–61
Dahl SG, Hals PA (1986) Pharmacokinetic and pharmacodynamic factors causing variability in response to neuroleptic drugs. In: Dahl SG, Gram LF, Paul SM, Potter WZ (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York, pp 266–274
Dahl SG, Strandjord RE (1977) Pharmacokinetics of chlorpromazine after single and chronic dosage. Clin Pharmacol Ther 21: 437–448
Gram LF (1977) Plasma level monitoring of tricyclic antidepressant therapy. Clin Pharmacokinet 2: 237–251
Gram LF, Pedersen OL, Kristensen CB, Bjerre M, Krag-Sorensen P (1982) Drug level monitoring in psychopharmacology: usefulness and clinical problems, with special reference to tricyclic antidepressants. Ther Drug Monit 4: 17–25
Hogarty GE, Ulrich RF, Mussare F, Aristigueta N (1976) Drug discontinuation among long-term successfully maintained schizophrenic outpatients. Dis Nerv Syst 37: 494–500
Hogarty GE, Schooler NR, Ulrich RF, Mussare F, Ferro P, Herron E (1979) Fluphenazine and social therapy in the aftercare of schizophrenic patients. Arch Gen Psychiatry 36: 1283–1294
Hulka BS, Cassel JC, Kupper LL (1976) Disparities between medications prescribed and consumed among chronic disease patients. In: Lasagna L (ed) Patient compliance. Futura Mount Kisco, New York, pp 123–152
Jørgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. In: Bridges JW, Chassaud LF (eds) Progress in drug metabolism, vol 9. Taylor and Francis, London, pp 111–174
Kane JM (1985) Antipsychotic drug side effects: their relationship to dose. J Clin Psychiatry 46: 16–21
Kane JM, Rifkin A, Woerner M, Reardon G, Sarantoakis S, Schibel D, Ramos-Lorenzi J (1983) Low dose neuroleptic treatment of outpatient schizophrenic patients. Arch Gen Psychiatry 40: 893–896
Kane JM, Woerner M, Lieberman J (1985) Tardive dyskinesia: prevalence, incidence, and risk factors. In: Casey DE, Chase TN, Christensen AY, Gerlach J (eds) Dyskinesia research and treatment. Springer, Berlin Heidelberg New York, pp 72–78
Larsen NE, Bolving Hansen L, Knudsen P (1985) Quantitative determination of perphenazine and its dealkylated metabolite using high-performance liquid chromatography. J Chromatogr 341: 244–250
Marder SR, van Putten T, Mintz J, McKenzie J, Lobell M, Faltico G, May PRA (1984)
Costs and benefits of two doses of fluphenazine. Arch Gen Psychiatry 41: 1025–1029
Neborsky RJ, Jankowski DS, Perel JM, Munson E, Depry DO (1984) Plasma/RBC haloperidol ratios and improvement in acute psychotic symptoms. J Clin Psychiatry 45: 10–13
Rifkin A, Quitkin F, Robiner DJ, Klein DJ (1977) Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remittent schizophrenics. I. Relapse after one year. Arch Gen Psychiatry 34: 43–47
Sjøqvist F, Bertilsson L. Asberg M (1980) Monitoring tricyclic antidepressants. Ther Drug Monit 25: 85–93
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1989 Springer-Verlag Berlin Heidelberg
About this paper
Cite this paper
Haffner, F. (1989). Perphenazine Serum Levels in Patients on Standard Doses. In: Dahl, S.G., Gram, L.F. (eds) Clinical Pharmacology in Psychiatry. Psychopharmacology Series, vol 7. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74430-3_32
Download citation
DOI: https://doi.org/10.1007/978-3-642-74430-3_32
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-74432-7
Online ISBN: 978-3-642-74430-3
eBook Packages: Springer Book Archive